Shares of Horizon Pharma Inc. (NASDAQ:HZNP) were up 1.8% during mid-day trading on Friday . The company traded as high as $19.25 and last traded at $19.02, with a volume of 1,640,269 shares. The stock had previously closed at $18.69.

Several brokerages have issued reports on HZNP. Vetr downgraded shares of Horizon Pharma from a “strong-buy” rating to a “buy” rating and set a $19.44 price objective for the company. in a research report on Monday, April 4th. Cowen and Company reaffirmed a “buy” rating on shares of Horizon Pharma in a research report on Saturday, April 2nd. Piper Jaffray Cos. reaffirmed a “buy” rating and issued a $44.00 price objective on shares of Horizon Pharma in a research report on Wednesday, April 13th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Horizon Pharma in a research report on Tuesday, April 12th. Finally, Mizuho reaffirmed a “buy” rating and issued a $34.00 price objective on shares of Horizon Pharma in a research report on Tuesday, April 12th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Horizon Pharma has a consensus rating of “Buy” and an average price target of $29.23.

The stock has a 50-day moving average of $17.52 and a 200 day moving average of $17.04. The stock has a market cap of $3.07 billion and a PE ratio of 248.31.

Horizon Pharma (NASDAQ:HZNP) last announced its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported $0.34 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.30 by $0.04. The firm had revenue of $204.70 million for the quarter, compared to analyst estimates of $197.73 million. The firm’s quarterly revenue was up 80.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.18 earnings per share. On average, equities analysts predict that Horizon Pharma Inc. will post $2.35 EPS for the current fiscal year.

In other news, Director Virinder Nohria sold 25,000 shares of Horizon Pharma stock in a transaction dated Wednesday, June 15th. The stock was sold at an average price of $17.69, for a total transaction of $442,250.00. Following the completion of the sale, the director now directly owns 189,836 shares in the company, valued at approximately $3,358,198.84. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Other large investors have recently made changes to their positions in the company. Deere & Co. purchased a new stake in shares of Horizon Pharma during the fourth quarter valued at about $1,873,000. Redwood Investments LLC raised its stake in shares of Horizon Pharma by 43.8% in the fourth quarter. Redwood Investments LLC now owns 111,682 shares of the biopharmaceutical company’s stock valued at $2,420,000 after buying an additional 34,008 shares in the last quarter. ProShare Advisors LLC raised its stake in shares of Horizon Pharma by 5.4% in the fourth quarter. ProShare Advisors LLC now owns 133,530 shares of the biopharmaceutical company’s stock valued at $2,894,000 after buying an additional 6,829 shares in the last quarter. Systematic Financial Management LP raised its stake in shares of Horizon Pharma by 100.4% in the fourth quarter. Systematic Financial Management LP now owns 152,340 shares of the biopharmaceutical company’s stock valued at $3,301,000 after buying an additional 76,335 shares in the last quarter. Finally, Swiss National Bank raised its stake in shares of Horizon Pharma by 2.5% in the fourth quarter. Swiss National Bank now owns 178,056 shares of the biopharmaceutical company’s stock valued at $3,858,000 after buying an additional 4,400 shares in the last quarter.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.